THERE IS GROWING AWARENESS THAT THE RESULTS OF randomized clinical trials
might not apply in a straightforward way to individual patients, even those within the trial. …

Mounting evidence suggests that there is frequently considerable variation in the risk of the
outcome of interest in clinical trial populations. These differences in risk will often cause …

The use of evidence from clinical trials to support decisions for individual patients is a form of
“reference class forecasting”: implicit predictions for an individual are made on the basis of …

Background: Risk of the outcome is a mathematical determinant of the absolute treatment
benefit of an intervention, yet this can vary substantially within a trial population, complicating …

AREVIEW OF THE RECURRENCE RISK LITERATURE uncovers several paradoxical
observations: thrombophilias predispose for a first episode of deep venous thrombosis (DVT) but …

Objective: We aimed to create an index to stratify cryptogenic stroke (CS) patients with patent
foramen ovale (PFO) by their likelihood that the stroke was related to their PFO. Methods: …

Importance Patent foramen ovale (PFO)–associated strokes comprise approximately 10% of
ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke …

Heterogeneity of treatment effect (HTE) refers to the nonrandom variation in the magnitude or
direction of a treatment effect across levels of a covariate, as measured on a selected scale…

Background The comparative effectiveness of percutaneous closure of patent foramen ovale
(PFO) plus medical therapy versus medical therapy alone for cryptogenic stroke is uncertain…

Objective To update the 2016 American Academy of Neurology (AAN) practice advisory for
patients with stroke and patent foramen ovale (PFO). Methods The guideline panel followed …